641 related articles for article (PubMed ID: 16166446)
1. Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma.
Inoue K; Karashima T; Fukata S; Nomura A; Kawada C; Kurabayashi A; Furihata M; Ohtsuki Y; Shuin T
Clin Cancer Res; 2005 Sep; 11(18):6669-77. PubMed ID: 16166446
[TBL] [Abstract][Full Text] [Related]
2. Combination with third-generation bisphosphonate (YM529) and interferon-alpha can inhibit the progression of established bone renal cell carcinoma.
Kurabayashi A; Inoue K; Fukuhara H; Karashima T; Fukata S; Kawada C; Shuin T; Furihata M
Cancer Sci; 2015 Aug; 106(8):1092-9. PubMed ID: 26041278
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel enhances the therapeutic effect of the angiogenesis inhibitor TNP-470 (AGM-1470) in metastatic human transitional cell carcinoma.
Inoue K; Chikazawa M; Fukata S; Yoshikawa C; Shuin T
Clin Cancer Res; 2003 Feb; 9(2):886-99. PubMed ID: 12576464
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis.
Izawa JI; Sweeney P; Perrotte P; Kedar D; Dong Z; Slaton JW; Karashima T; Inoue K; Benedict WF; Dinney CP
Clin Cancer Res; 2002 Apr; 8(4):1258-70. PubMed ID: 11948141
[TBL] [Abstract][Full Text] [Related]
5. Combined therapy with a new bisphosphonate, minodronate (YM529), and chemotherapy for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice.
Yano S; Zhang H; Hanibuchi M; Miki T; Goto H; Uehara H; Sone S
Clin Cancer Res; 2003 Nov; 9(14):5380-5. PubMed ID: 14614023
[TBL] [Abstract][Full Text] [Related]
6. The bisphosphonate YM529 inhibits osteoblastic bone tumor proliferation of prostate cancer.
Yonou H; Ochiai A; Ashimine S; Maeda H; Horiguchi Y; Yoshioka K; Ogawa Y; Hatano T; Tachibana M
Prostate; 2007 Jun; 67(9):999-1009. PubMed ID: 17440967
[TBL] [Abstract][Full Text] [Related]
7. A novel bisphosphonate minodronate (YM529) specifically inhibits osteolytic bone metastasis produced by human small-cell lung cancer cells in NK-cell depleted SCID mice.
Zhang H; Yano S; Miki T; Goto H; Kanematsu T; Muguruma H; Uehara H; Sone S
Clin Exp Metastasis; 2003; 20(2):153-9. PubMed ID: 12705636
[TBL] [Abstract][Full Text] [Related]
8. Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer.
Kim SJ; Uehara H; Yazici S; He J; Langley RR; Mathew P; Fan D; Fidler IJ
Cancer Res; 2005 May; 65(9):3707-15. PubMed ID: 15867366
[TBL] [Abstract][Full Text] [Related]
9. Sagopilone inhibits breast cancer bone metastasis and bone destruction due to simultaneous inhibition of both tumor growth and bone resorption.
Strube A; Hoffmann J; Stepina E; Hauff P; Klar U; Käkönen SM
Clin Cancer Res; 2009 Jun; 15(11):3751-9. PubMed ID: 19470728
[TBL] [Abstract][Full Text] [Related]
10. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
[TBL] [Abstract][Full Text] [Related]
11. A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo.
Sato K; Yuasa T; Nogawa M; Kimura S; Segawa H; Yokota A; Maekawa T
Br J Cancer; 2006 Nov; 95(10):1354-61. PubMed ID: 17043684
[TBL] [Abstract][Full Text] [Related]
12. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel.
Inoue K; Slaton JW; Davis DW; Hicklin DJ; McConkey DJ; Karashima T; Radinsky R; Dinney CP
Clin Cancer Res; 2000 Jul; 6(7):2635-43. PubMed ID: 10914704
[TBL] [Abstract][Full Text] [Related]
13. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
Peng H; Sohara Y; Moats RA; Nelson MD; Groshen SG; Ye W; Reynolds CP; DeClerck YA
Cancer Res; 2007 Oct; 67(19):9346-55. PubMed ID: 17909043
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis.
Zheng Y; Zhou H; Brennan K; Blair JM; Modzelewski JR; Seibel MJ; Dunstan CR
Bone; 2007 Feb; 40(2):471-8. PubMed ID: 17092788
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma.
Inoue K; Slaton JW; Perrotte P; Davis DW; Bruns CJ; Hicklin DJ; McConkey DJ; Sweeney P; Radinsky R; Dinney CP
Clin Cancer Res; 2000 Dec; 6(12):4874-84. PubMed ID: 11156247
[TBL] [Abstract][Full Text] [Related]
16. Effects of the combination of RAD001 and docetaxel on breast cancer stem cells.
Zhang X; Zhang S; Liu Y; Liu J; Ma Y; Zhu Y; Zhang J
Eur J Cancer; 2012 Jul; 48(10):1581-92. PubMed ID: 22420943
[TBL] [Abstract][Full Text] [Related]
17. Frequent administration of angiogenesis inhibitor TNP-470 (AGM-1470) at an optimal biological dose inhibits tumor growth and metastasis of metastatic human transitional cell carcinoma in the urinary bladder.
Inoue K; Chikazawa M; Fukata S; Yoshikawa C; Shuin T
Clin Cancer Res; 2002 Jul; 8(7):2389-98. PubMed ID: 12114444
[TBL] [Abstract][Full Text] [Related]
18. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
Wang Z; Zhou J; Fan J; Qiu SJ; Yu Y; Huang XW; Tang ZY
Clin Cancer Res; 2008 Aug; 14(16):5124-30. PubMed ID: 18698030
[TBL] [Abstract][Full Text] [Related]
19. Oral silibinin inhibits in vivo human bladder tumor xenograft growth involving down-regulation of survivin.
Singh RP; Tyagi A; Sharma G; Mohan S; Agarwal R
Clin Cancer Res; 2008 Jan; 14(1):300-8. PubMed ID: 18172282
[TBL] [Abstract][Full Text] [Related]
20. A conventional preclinical schedule of cisplatin is more effective than a metronomic frequent bolus schedule for urothelial carcinoma.
Levitt JM; Jian W; Lerner SP; Sonpavde G
Urol Oncol; 2013 Feb; 31(2):234-40. PubMed ID: 21723160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
